Aptevo Therap | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -2.23, missing the estimate of USD -2.09.

EBIT: As of FY2025 Q3, the actual value is USD -7.61 M.

Segment Revenue

• The company did not report any product revenue for the current period and expects to continue incurring significant expenses and operating losses as it advances its product candidates through development and clinical trials.

Operational Metrics

• Net Loss: For the nine months ended September 30, 2025, the net loss was - $20.2 million, compared to - $17.8 million for the same period in 2024.
• Research and Development Expenses: Increased by $0.5 million, from $10.5 million for the nine months ended September 30, 2024, to $11.0 million for the same period in 2025.
• General and Administrative Expenses: Increased by $1.6 million, from $7.7 million for the nine months ended September 30, 2024, to $9.3 million for the same period in 2025.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used was - $20.4 million, compared to - $18.0 million for the same period in 2024.
• Net Cash Provided by Financing Activities: $32.7 million for the nine months ended September 30, 2025, primarily due to the exercise of warrants and issuance of common stock.

Unique Metrics

• Cash and Cash Equivalents: As of September 30, 2025, cash and cash equivalents were $21.1 million, compared to $8.7 million as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue developing its pipeline of immuno-oncology candidates using its ADAPTIR and ADAPTIR-FLEX platform technologies. It aims to expand its product pipeline with new trispecific assets, APVO451 and APVO452, targeting prostate cancers and a broad range of solid tumors.
• Non-Core Business: The company raised $18.7 million net in the third quarter and $4.1 million net since quarter end, extending its cash runway well into 4Q26, enabling it to reach important clinical milestones next year.